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A B S T R A C T
Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by severe joint inflammation and
bone destruction as the result of increased numbers and activity of osteoclasts. RA is often associated with
metabolic syndrome, whereby elevated levels of LDL are oxidized into oxLDL, which might affect osteoclasto-
genesis. In this study, we induced antigen-induced arthritis (AIA) in Apoe−/− mice, which spontaneously de-
velop high LDL levels, to investigate the effects of high LDL/oxLDL levels on osteoclast differentiation and bone
destruction. Whereas basal levels of bone resorption were comparable between naive WT and Apoe−/− mice,
induction of AIA resulted in a significant reduction of bone destruction in Apoe−/− mice as compared to WT
controls. In line with that, the TRAP+ area on the cortical bone was significantly decreased. The absence of Apoe
did affect neither the numbers of CD11b+Ly6Chigh and CD11b−/Ly6Chigh osteoclast precursors (OCPs) in the BM
of naïve mice nor their in vitro osteoclastogenic potential as indicated by comparable mRNA expression of
osteoclast markers. Addition of oxLDL, but not LDL, to pre-osteoclasts from day 3 and mature osteoclasts from
day 6 of osteoclastogenesis strongly reduced the number of TRAP+ osteoclasts and their resorptive capacity. This
coincided with a decreased expression of various osteoclast markers. Interestingly, oxLDL significantly lowered
the expression of osteoclast-associated receptor (Oscar) and the DNAX adaptor protein-12 encoding gene Tyrobp,
which regulate the immunoreceptor tyrosine-based activation motif (ITAM) co-stimulation pathway that is
strongly involved in osteoclastogenesis. Collectively, our findings suggest that under inflammatory conditions in
the joint, high LDL levels lessen bone destruction during AIA, probably by formation of oxLDL that inhibits
osteoclast formation and activity through modulation of the ITAM-signaling.
1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease that
affects the joints, and is characterized by synovial inflammation and
excessive bone destruction [1,2]. Elevated production of pro-in-
flammatory mediators leads to increased levels of macrophage colony-
stimulating factor (M-CSF) and receptor activator of nuclear factor-κB
(RANK) ligand (RANKL), which induce the differentiation of myeloid
precursors into osteoclasts [3,4] that is accompanied by increased ex-
pression of osteoclast-specific markers [5–7]. In mice, particularly
CD11b+Ly6Chigh and CD11b−Ly6Chigh precursors in the bone marrow
(BM) are known to increase during experimental inflammatory arthritis
and they are recruited to the inflamed joint where they can differentiate
into osteoclasts [8,9]. Next to RANK/RANKL signaling, the balance
between the immunoreceptor tyrosine-based activation motif (ITAM)
and the immunoreceptor tyrosine-based inhibitory motif (ITIM) co-sti-
mulatory signaling plays an important role in modulating osteoclasto-
genesis [10–12]. Within this system, osteoclast-associated receptor
(OSCAR) and paired immunoglobulin-like receptor A (PIR-A) activate
ITAM-signaling via association with Fc receptor common γ-chain
(FcRγ), whereas the triggering receptor expressed on myeloid cells-2
(TREM-2) activates ITAM-signaling upon binding to DNAX adaptor
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protein of 12 kDa (DAP12) [13,14]. Conversely, the immunoglobulin-
like receptor B (PIR-B) signals through an ITIM motif and as such ne-
gatively regulates the ITAM-signaling, and thus osteoclastogenesis [15].
As the activation of the ITAM-pathway may further drive osteoclast
differentiation and function, its regulation can be particularly relevant
in inflammatory immune-based diseases like RA [10]. RA is often as-
sociated with metabolic syndrome, and both are characterized by ele-
vated levels of low density lipoproteins (LDL) that are oxidized into
oxLDL in inflammatory environments [16–18]. Therefore, the enhanced
presence of oxLDL during inflammatory arthritis might affect differ-
entiation and activation of osteoclasts, causing bone destruction in the
arthritic joints. In order to investigate this, we used Apolipoprotein E
deficient (Apoe−/−) mice that are commonly used as a model for hy-
percholesterolemia [19]. Apolipoprotein E (Apoe) is a lipoprotein that
regulates LDL transportation and its absence strongly elevates circu-
lating LDL levels in humans as well as in mice [20]. In this study, we
elicited antigen-induced arthritis (AIA) in knee joints of Apoe−/− mice
and their wild type (WT) controls to investigate the effects of high LDL
levels and their oxidation to oxLDL, increased by the inflammatory
milieu, on osteoclast-mediated bone destruction. Further, using in vitro
experiments, we aimed at identification of molecular pathways in-




B6.129P2-Apoetm1Unc/J mice (JAX strain) and wild type C57Bl/6J
controls were obtained from the Charles River Laboratory (Leiden, the
Netherlands). All mice were housed in filter-top cages and received a
standard chow diet and acidified water ad libitum. Male mice between
10 and 12weeks were used in all the experiments, which were per-
formed in accordance with the Dutch regulations and guidelines for
care and use of laboratory animals. All animal studies were approved by
the Radboud University's Animal Experiment Committee, Nijmegen-the
Netherlands (RU-DEC 2014-191).
2.2. Induction of antigen–induced arthritis
Mice were immunized with 100 μg/ml of methylated bovine serum
albumin (mBSA; Sigma–Aldrich) emulsified in 100 μl Freund's complete
adjuvant (CFA). Injections were divided over the flanks and the footpad
of the front paws. Heat killed Bordetella Pertussis was administered as an
additional adjuvant intraperitoneally. One week later, two sub-
cutaneous injections of 50 μg of mBSA/CFA were given as a booster in
the neck region. Two weeks after these booster injections, arthritis was
induced in the right knee joint by intra-articular injection of 60 μg of
mBSA in 6 μl saline.
2.3. Histology
Total knee joints were dissected, fixed in phosphate-buffered for-
malin (pH 7.4), decalcified in ethylenediaminetetraacetic acid (EDTA)
and subsequently embedded in paraffin wax. Coronal sections of 7 μm
of various depths, representing the whole knee joint, were stained with
hematoxylin & eosin (H&E) for histological analysis. Bone destruction
was evaluated in 13 well-defined areas of the knee joint (shown in
Supplementary File 1) and scored arbitrarily on a scale from 0 (no
erosion) to 3 (connection between joint cavity and bone marrow). Total
knee joint sections were stained for tartrate-resistant acid phosphatase
(TRAP), using the Leukocyte Acid Phosphatase Kit (Sigma-Aldrich)
according to the manufacturer's protocol. The amount of TRAP+ area
present along the cortical bone and trabecular bone within the bone
marrow (BM) cavity, representing osteoclasts, was measured in the
arthritic joints as percentage (%) of positive area above a fixed
threshold using Leica Application Suite software (Leica Microsystems).
2.4. Flow cytometry
Numbers of osteoclast precursors in the BM were determined with
flow cytometry. Bone marrow was isolated from femurs and tibias of
mice by flushing the marrow cavity with medium and passing the cell
suspension through a strainer. After lysis of erythrocytes, bone marrow
cells were incubated with Fc-blocking antibody (BD Pharmingen anti-
mouse CD16/CD32, clone 2.4G2; BD Biosciences, San Jose, CA, USA),
followed by staining with the following mix of antibodies: CD11b-
fluorescein isothiocyanate (FITC), CD90.2-phycoerythrin (PE), CD45R/
B220-PE, CD49b-PE, NK1.1-PE, Ly6G-PE, Ly6C-allophycocyanin-cya-
nine 7 (APC-Cy7), and F4/80-PE-Cy7 (all BD Biosciences). Samples
were acquired with a Gallios flow cytometer (Beckman Coulter Life
Sciences, Indianapolis, IN, USA).
2.5. In vitro osteoclast differentiation
Following BM isolation, total BM cells were seeded into 96-well
plates at a density of 105 cells/well and cultured up to 7 days in 100 μl
of α-minimum essential medium (Thermo Fisher Scientific), supple-
mented with 5% FCS, penicillin/streptomycin, 30 ng/ml recombinant
mouse (rm)M-CSF, and 20 ng/ml rmRANKL (R&D Systems). Culture
medium was refreshed after 3 days.
2.6. oxLDL preparation and stimulation of osteoclasts
LDL was isolated by single-spin density gradient ultracentrifugation
from EDTA-treated blood from healthy volunteers and oxidized as
previously described [21]. At various time-points (day 3, 5 or day 6) of
osteoclastogenesis, preosteoclasts or yet mature osteoclasts were sti-
mulated with either 10 μg/ml oxLDL or 10 μg/ml LDL-C as control and
the medium was refreshed every 3 days. This concentration was chosen
to resemble the LDL-C levels in vivo [22].
2.7. RNA isolation and qRT-PCR
RNA from osteoclast cultures was isolated with TRIzol reagent
(Sigma-Aldrich) at different time-points during osteoclastogenesis (days
0, 3, 4, 6 and 7). Briefly, mRNA concentration was measured with a
Nanodrop spectrophotometer and subsequently reverse-transcribed into
complementary DNA (cDNA) using oligo (dT) primers. qRT-PCR was
performed using the Applied Biosystems StepOnePlus RT-PCR System
(Thermo Fisher Scientific). Specific primer sequences used to assess
gene expression are listed in Table 1. Glyceraldehyde 3-phosphate de-
hydrogenase (Gapdh) was used as housekeeping gene. Samples were
normalized for the expression of Gapdh by calculating the comparative
threshold: −ΔCt=− (Ct gene of interest − Ct Gapdh).
2.8. Determination of TRAP activity in the supernatants
Culture supernatants were collected after 7 days of differentiation
and TRAP activity was measured with a colorimetric assay. Briefly, p-
nitrophenyl phosphate (NewEngland Biolabs) was diluted in buffer
containing 420mM acetic acid (Sigma-Aldrich) and 160mM tartrate
solution (Merck) and added 1:1 to culture supernatant. After 1 h, the
reaction was stopped with 0.5 M NaOH (Sigma-Aldrich) and the ab-
sorbance at 405 nm was determined using a spectrophotometric plate
reader (Bio-Rad Laboratories).
2.9. Resorption assay on calcium phosphate–coated plates
Bone marrow cells were seeded at a density of 105 cells/well onto
96-well biomimetic hydroxyapatite-like–coated plates that were pre-
pared as previously described [23]. Preosteoclasts or mature osteoclasts
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were stimulated with LDL/oxLDL starting from day 3 and day 5, re-
spectively, and the medium was refreshed every 3 days. At day 10 the
medium was removed from the wells, then 100 μl/well of distilled
water was added to lyse the cells. To analyze pit-formation the coated
layer was stained with a Von Kossa staining. Briefly, a 5% aqueous
silver nitrate was added and incubated in the dark. Afterwards, wells
were washed with water and incubated with 5% sodium carbonate in
4% formalin. Digital images were obtained with a camera mounted on
an inverted-light microscope. The percentage of resorbed bone area was
quantified using the Leica Application Suite software (Leica Micro-
systems).
2.10. Statistics
Statistics was performed using GraphPad Prism version 5.0
(GraphPad Software Inc.). Differences between two groups were tested
using a two-tailed Student's t-test for comparing parametric variables,
Mann-Whitney test for non-parametric variables (e.g. histological
score) and multiple comparisons were tested using One–way ANOVA
followed by Bonferroni's multiple comparison test. P values < 0.05
were considered significant. Data are presented as the mean ± SEM.
3. Results
3.1. Apoe−/− mice show reduced bone destruction during AIA
First, we determined bone destruction in knee joints of hypercho-
lesterolemic Apoe−/− mice and their WT controls during AIA.
Histological analysis showed less severe bone erosion in arthritic
Apoe−/− mice as compared to their arthritic WT controls (Fig. 1a).
Quantification showed a significant reduction (by 25%) in bone erosion
in Apoe−/− mice (Fig. 1b) when compared to WT mice. Only minor but
comparable bone erosion was observed in naive joints of WT and
Apoe−/− mice (Fig. 1c and d).
3.2. Arthritic Apoe−/− mice develop less osteoclasts along the cortical bone
Because we found less bone destruction in Apoe−/− mice during
AIA, we next determined by enzymehistochemical TRAP staining
whether this was due to a lower number of multinucleated resorbing
osteoclasts. In line with the decreased bone destruction, at day 21 of
AIA we observed a significant reduction in the amount of TRAP+ area
(1.9-fold decrease) as well as the number of osteoclasts along the cor-
tical bone of Apoe−/− mice when compared to WT controls (Fig. 2b and
c). Further, we observed a different morphology of the osteoclasts
present on the cortical bone, with the Apoe−/− cells being more flat-
tened as compared to WT control cells (Fig. 2a).
3.3. Apoe deficiency does not affect the number of osteoclast precursors in
the bone marrow and their osteoclastogenic potential
Next, we determined whether the absence of Apoe by itself could be
the direct cause of the observed reduction in the number of osteoclasts.
Flow cytometric analysis showed that the number of CD11b+Ly6Chigh
and CD11b−Ly6Chigh cells, which are the main osteoclast precursors
(OCPs) [8,9], were comparable in the BM of Apoe−/− and WT mice
prior to induction of AIA. Interestingly, the percentage of
CD11b−Ly6Chigh cells in the BM was even significantly increased in
arthritic Apoe−/− mice (Fig. 3a and b). Next, we investigated whether
the absence of Apoe itself altered their osteoclastogenic potential. We
observed comparable kinetics in the expression of various osteoclast
markers in differentiating osteoclasts from WT and Apoe−/− BM cells in
vitro (Fig. 3c). Underlining this finding, no significant differences were
observed in the number of TRAP+ and multinucleated osteoclasts ob-
tained from WT and Apoe−/− cultures (58 ± 10 vs. 52 ± 7 osteo-
clasts, respectively) (Fig. 3d). Moreover, we found no difference in the
amount of TRAP+ area between arthritic WT and Apoe−/− mice in the
trabecular bone within the BM cavity, which is not directly in contact
with inflammatory mediators in the arthritic synovium (Fig. 3e and f).
Together these data suggest that increased LDL oxidation in the in-
flammatory milieu rather than the Apoe deficiency in the arthritic joint
may account for the differences in the number of osteoclasts on cortical
bone.
3.4. oxLDL, but not LDL, blocks the differentiation of pre-osteoclasts into
mature osteoclasts
Because the number of osteoclasts exclusively was reduced in the
arthritic environment, we hypothesised that local inflammation may be
involved. Apoe−/− mice spontaneously develop elevated levels of LDL,
and this LDL is oxidized into oxLDL in inflamed areas. Therefore, we
investigated whether LDL or oxLDL affected in vitro osteoclast differ-
entiation. First, at day 3 of differentiation pre-osteoclasts were stimu-
lated with oxLDL or LDL for 24 h and lipid uptake was detected by Oil
Red O staining. As expected, oxLDL accumulated within the cells,
whereas LDL did not (Fig. 4a). Pre-osteoclasts exposed to oxLDL for
24 h showed a significant decrease of the mRNA levels of various os-
teoclast markers. In contrast, the levels of Adgre1, the gene encoding for
Table 1
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F4/80 as macrophage marker remained significantly higher, under-
lining a blockage of osteoclast differentiation (Fig. 4b). Next, to assess
the effects of oxLDL on osteoclast formation, the cells were further
cultured up to 7 days. In agreement with our findings on the mRNA
level, oxLDL, but not LDL, determined a nearly complete inhibition
(94% less than in control cells) of the number of TRAP+ and multi-
nucleated cells (Fig. 4c). This reduction was not due to cytotoxic effects
of oxLDL, as indicated by the comparable fluorescence intensity signals
after a DAPI staining among non-stimulated, LDL and oxLDL-stimulated
cells (Fig. 4d). Although also apoptotic cells can internalize the DAPI
stain qualitative assessment of the DAPI positive cells showed no sig-
nificant differences in the nuclear morphology (data not shown), sug-
gesting that oxLDL does not affect viability.
3.5. oxLDL, but not LDL, inhibits the further fusion of multinucleated
osteoclasts and their capacity to break down the bone mineral matrix
At day 6, mature osteoclasts were stimulated for 24 h to investigate
the effects of LDL and oxLDL at a later stage of differentiation. We
found a significant reduction of TRAP+ and multinucleated cells upon
oxLDL exposure (46% reduction as compared to control) (Fig. 5a and
b). In accordance with the inhibition of osteoclastogenesis, we found
that also osteoclast–mediated degradation of biomimetic hydro-
xyapatite-coated plates was strongly and significantly impaired by
oxLDL both when pre-osteoclasts and mature osteoclasts were stimu-
lated (Fig. 5c), indicating that exposure to oxLDL can inhibit the re-
sorption machinery at different stages of osteoclastogenesis. Finally, as
TRAP activity is commonly accepted as marker for bone resorption, we
determined its secretion in the culture supernatants and found that
exposure to oxLDL, but not LDL, of both pre-osteoclasts and mature
osteoclasts significantly inhibited TRAP activity (Fig. 5d).
3.6. oxLDL strongly down-regulates the expression of molecules involved in
the ITAM co-stimulation pathway
To identify a possible mechanism responsible for the effects of
oxLDL on osteoclasts, we determined whether oxLDL affected the
RANK/RANKL signaling, which is crucial to induce osteoclastogenesis.
We found that oxLDL stimulation of pre-osteoclasts did not change the
mRNA levels of Tnfrsf11a and Csf1r encoding genes for RANK and M-
CSFR, respectively (Fig. 6a). Next to RANK/RANKL signaling, factors
involved in the co-stimulatory pathway play an important role in sti-
mulating osteoclastogenesis and bone destruction. Therefore, we ad-
dressed whether oxLDL affected the expression of these factors. Inter-
estingly, the mRNA of the immunoreceptor Oscar was strongly and
significantly down-regulated in pre-osteoclasts by oxLDL. Although the
expression of Trem2 was significantly increased, we found that the le-
vels of Tyrobp, a gene that codes for DAP-12, which binds to TREM2,
were significantly down-regulated upon oxLDL exposure. In contrast,
the expression of other factors of the ITAM/ITIM co-stimulatory
pathway such as Pira, Fcrg and Pirb - did not change upon oxLDL
(Fig. 6b). Further, we assessed the expression of Fcγ receptors (FcγRs)
as they are involved in ITAM-mediated induction of osteoclastogenesis
and found that oxLDL significantly up-regulated the mRNA of Fcgr3,
which has been associated with the inhibition of osteoclastogenesis
[24] (Fig. 6c). These data suggest that at later stages of osteoclasto-
genesis, oxLDL does not affect either the RANK/RANKL signaling or the
response to M-CSF-induced differentiation of pre-osteoclasts, but rather
targets the ITAM co-stimulatory pathway to inhibit the further differ-
entiation of pre-osteoclasts into mature and functional cells.
Fig. 1. Apoe−/− mice develop less bone destruction during AIA. a) Representative photomicrographs of bone erosion as determined by histology in arthritic Apoe−/−
mice and their wild type (WT) controls at day 21 after induction of antigen-induced arthritis (AIA). Original magnification, 200×. (F= Femur). b) Quantification of
bone destruction showed that arthritic Apoe−/− mice had a significant reduction of bone erosions as compared to WT controls. c) In contrast, naive knee joints of WT
and Apoe−/− mice showed minor but comparable erosions, due to physiologic bone remodeling. d) Quantification of bone remodeling in naïve mice. Error bars
represent the mean ± SEM of 10 mice (arthritic) and 8 mice (naïve). (**= P < 0.01 versus WT controls).
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4. Discussion
In the present study, we show that high LDL levels in Apoe−/− mice
in combination with local inflammation resulted in decreased bone
destruction and reduction of the number of osteoclasts in the knee
joints after local induction of AIA. Further, we show that oxLDL but not
LDL prevents the differentiation of osteoclasts, and their function
probably by decreasing the activity of the ITAM co-stimulatory
pathway.
RA is often accompanied by dyslipidemia, characterized by high
levels of LDL and low levels of high density lipoprotein (HDL) choles-
terol [25,26] and LDL has been proposed as a novel serum marker to
predict radiographic progression in RA patients [27]. However the re-
lation between high LDL levels and bone erosion in RA is still a matter
of debate. In the serum transfer-induced arthritis (STIA) model Archer
et al. found that Apoe−/− mice fed a western-type diet (WD) developed
enhanced synovial inflammation, although bone destruction was not
affected [28]. In line with this, a previous study from our lab showed
increased early ectopic bone formation in dyslipidemic mice during
experimental osteoarthritis, likely due to the enhanced production of
transforming growth factor-beta (TGF-β) by synovial macrophages
[29,30]. TGF-β strongly inhibits osteoclast formation and activity
[31,32]. As we found that elevated levels of LDL and their increased
oxidation during AIA in the Apoe−/− mice decreased bone destruction
it can be that oxLDL acts as an anabolic factor by inducing the local
production of TGF-β, thus decreasing osteoclast formation and bone
destruction. Therefore, further studies including intra-articular injec-
tions of oxLDL will help to shed light on the effect of oxLDL on the
development of joint destruction.
In RA patients the permeability of the endothelium is altered which
allows a substantial access of LDL from the blood stream to the sub-
endothelial layer [33] and joint tissues, and as such LDL levels in sy-
novial fluids of RA patients resemble those in the blood [34]. After
entering the inflamed joint, LDL becomes oxidized to oxLDL through
the action of pro-inflammatory cytokines that stimulate the release of
reactive oxygen species by inflammatory cells (ROS) [35–37]. Our
findings show that hypercholesterolemic Apoe−/− mice developed less
bone destruction owed to a substantial reduction of the number of os-
teoclasts in the arthritic knee joint. Apoe−/− mice are a widely accepted
mouse model for hypercholesterolemia [38,39]. Apart from regulating
LDL levels [40], APOE has been described as an inhibitor of various
immune cells [41,42] and its absence may stimulate systemic in-
flammation thereby potentiating bone erosion. However, studying
Apoe−/− mice with high LDL levels, only physiological bone re-
modeling was found in naive knee joints not different from that in WT
mice. In addition, in the absence of an inflammatory trigger, APOE did
Fig. 2. Induction of AIA in Apoe−/− mice results in the reduction of osteoclast numbers on the cortical bone. a) Representative photomicrographs of TRAP positive
(TRAP+) cells along the bone surface in total knee joint sections of WT and Apoe−/− mice and WT controls at day 21 after induction of AIA. b) Quantification of
TRAP+ area along the cortical bone surface showed that arthritic Apoe−/− mice had a significant reduction of osteoclast number as compared to WT controls. c)
Quantification of the number of TRAP+ osteoclasts along the cortical bone. Error bars represent the mean ± SEM of 10 arthritic mice/group (**= P < 0.01 versus
WT controls). Original magnification, 200×.
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not affect the percentage of OCPs present in the bone marrow nor the
kinetics of expression of osteoclast markers and their osteoclastogenic
potential. This is in accordance with a previous study by Schilling et al.
that described that mice lacking Apoe displayed an increased trabecular
bone volume caused by an increased bone formation rate, probably due
to undercarboxylation of osteocalcin that is an inhibitor of osteo-
blastogenesis [43]. Similarly, Nikolov et al. reported that Apoe−/− mice
had higher cortical and trabecular bone mass than control WT mice at
the basal level due to increased osteoblast -mediated bone formation
[44]. However, it has to be noted that in contrast to our study in which
we used young, 12-weeks old, male mice they used 20-weeks old female
mice, suggesting that under hypercholesterolemic conditions both sex
and age have an additional effect on bone metabolism. In our study we
showed that neither high levels of LDL alone nor Apoe deficiency by
itself, promote osteoclastogenesis and bone erosion. Further, increased
LDL oxidation in arthritic Apoe−/− mice did not lead to a reduction of
Fig. 3. The absence of Apoe does not affect the number of osteoclast precursors in the bone marrow or their osteoclastogenic potential. a) Comparable percentages of
CD11b+Ly6Chigh and CD11b−Ly6Chigh osteoclast precursors (OCPs) were present in the bone marrow (BM) of naïve wild type (WT) and Apoe−/− mice (n= 6 mice/
group). b) Notably, whereas we observed decreased numbers of osteoclasts at day 21 after AIA induction, Apoe−/− mice showed a significantly higher percentage (%)
of CD11b−Ly6Chigh OCPs compared to WT mice. c) Comparable messenger RNA (mRNA) expression levels of various osteoclast markers were determined at various
time-points during osteoclastogenesis in WT and Apoe−/− bone marrow (BM) cells (n=6 mice/group). Colony stimulating factor 1 receptor (Csf1r); Tumor necrosis
factor receptor superfamily member 11a (Tnfrsf11a); Nuclear factor of activated T cells 1 (Nfatc1); Dendritic cells specific transmembrane protein (Dcstamp); Acid
phosphatase 5 (Acp5); Calcitonin receptor (Calcr); Chloride channel-voltage sensitive 7 (Clcn7); Carbonic anhydrase 2 (Ca2); Matrix metallopeptidase 9 (Mmp9);
Cathepsin K (Ctsk); d) Quantification of TRAP+ osteoclasts shows no differences in the number of osteoclasts. e) Moreover, as indicated in representative micro-
photographs, no differences in the amount of TRAP+ osteoclasts were present in the trabecular bone within the BM. Original magnification, 200×. f) Quantification
of the TRAP+ area within the BM expressed as percentage. Error bars represent the mean ± SEM of 10 mice (*= P < 0.05 compared to WT controls).
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bone mass as determined by measuring the surface of the cortical bone
in the arthritic knee joints (data not shown). Together, this suggests
that Apoe deficiency and high LDL levels can interfere with osteo-
blastogenesis and bone formation, whereas bone resorption remains
unaffected. In contrast, LDL receptor deficient (Ldlr−/−) mice, which
represent another model of hypercholesterolemia, showed increased
bone mass caused by impaired osteoclast-mediated bone resorption
[45], which may be due to the fact that the LDL receptor is required to
allow cholesterol uptake into cells under physiologic conditions [46].
Some studies have described that hypercholesterolemia and in-
creased lipid oxidation reduce bone mass [47–49]. Discrepancies be-
tween our and previous findings may be explained by the fact that we
studied Apoe−/− mice that received a standard chow diet, while these
previous studies used a high fat diet (HFD). HFD massively elevates LDL
levels and its oxidation [47,49], thus contributing to increase of sys-
temic inflammation that can affect bone formation [50,51].
Interestingly, although LDL levels as found in Apoe−/− mice fed a
standard chow diet do not change bone destruction in a normal joint, in
combination with synovial inflammation a strong reduction in devel-
opment of bone destruction was observed that coincided with a sig-
nificant reduction of osteoclasts on the cortical bone. This reduction
was not due to a difference in OCP numbers since the numbers of
CD11b+Ly6Chigh and CD11b−Ly6Chigh, the main OCPs, were not de-
creased in BM of arthritic Apoe−/− mice and their WT controls. This
suggests that even though Apoe−/− mice developed decreased synovial
inflammation [52] the generation of OCPs in the BM and their potential
differentiation into osteoclasts in the knee joints is not affected. Inter-
estingly, bone areas within the same knee joint that did not have direct
contact with inflammatory cells (like the BM cortical bone) showed a
similar amount of TRAP+ osteoclasts between the two strains again
indicating that high LDL levels alone without oxidation do not impair
the number of osteoclasts. Therefore, we assume that enhanced LDL
oxidation in the arthritic synovium of Apoe−/− mice may lead to a
locally induced reduction of osteoclast numbers and diminished bone
destruction.
As we could not detect oxLDL directly within the inflamed knee
joints as the heterogeneity of oxLDL, due to different degrees as well as
specific epitopes of oxidation, makes its detection in vivo very difficult
[37,53], we further investigated the effect of LDL/oxLDL in an in vitro
osteoclastogenesis assay. Our findings strongly point out that oxLDL
prevented the differentiation into multinucleated osteoclasts both when
given in an early and later stage of osteoclastogenesis, thereby strongly
reducing gene expression of osteoclast markers and resorption on bio-
mimetic hydroxyapatite-like–coated plates. The decrease in osteoclas-
togenesis was not due to cell death since DAPI staining showed com-
parable numbers of cells in treated versus non-treated groups. In
contrast to oxLDL, we observed no significant in vitro effect of LDL on
osteoclast formation and activity and LDL only mildly reduced resorp-
tion. The latter may also be an oxLDL effect since the extended time
frame of the cultures needed to investigate the resorption may have led
to a partial oxidation of native LDL into oxLDL in the culture super-
natant. Our findings are in line with the study of Mazière et al. [54]
who also found that oxLDL blocks the in vitro differentiation of OCPs
into osteoclasts. However, in contrast to their studies in which oxLDL
was added to very early stages of OCPs we focused more on further
differentiated pre-osteoclasts. The reason for this is that OCPs coming
from the BM that enter the arthritic joint probably exhibit a more de-
veloped differentiation stage that is further steered by the inflammatory
process within the inflamed synovium. Interestingly, Mazière et al.
found that oxLDL blocks the in vitro differentiation of BM OCPs into
osteoclasts upstream by inhibiting the RANK/RANKL signaling axis,
which is crucial for induction of osteoclastogenesis [54]. In contrast, we
found that stimulation with oxLDL when added later on in the differ-
entiation process of osteoclastogenesis had no effects on the expression
of RANK, but rather on some of the factors involved in the likewise
important ITAM-mediated signaling pathway. The co-stimulatory
pathway for osteoclastogenesis is triggered via phosphorylation of the
ITAM domain present on the adapter molecules γ-chain which is paired
with the receptors OSCAR, PIRA and FcγRs and DAP12 with TREM2
[55–57]. Of note, Oscar mRNA levels were sharply down-regulated in
pre-osteoclasts exposed to oxLDL, implying that fewer OSCAR receptors
are available to trigger the ITAM-pathway through the γ-chain. In
contrast, Trem2 mRNA was significantly up-regulated by oxLDL. How-
ever, as we find that its signaling molecule Tyrobp is strongly decreased,
it is unlikely that the up-regulation of Trem2 leads to a greater activa-
tion of the co-stimulatory pathway of osteoclastogenesis.
Previous studies reported that TREM-2 expression steers the differ-
entiation of M2-like macrophages [58,59]. Moreover, pre-osteoclasts
exposed to oxLDL also showed increased mRNA levels of F4/80 which is
a major macrophage marker [60,61]. These results indicate that cells
exposed to oxLDL differentiate toward the macrophage rather than the
osteoclast lineage despite high levels of RANKL and M-CSF. Moreover,
FcγRIII, which has been shown to inhibit osteoclastogenesis by se-
questering the γ-chain and withholding its association with osteoclast-
inducer immune receptors like OSCAR [24], was significantly up-
regulated. It has to be mentioned that in this study we predominantly
focused on the ITAM co-stimulatory signaling pathway for osteoclas-
togenesis and therefore cannot rule out that oxLDL interferes with other
signaling pathways (i.e.: IL-6, TNF-α) that are relevant for bone de-
struction in RA. Together, these observations substantiate the hypoth-
esis that at later stages of osteoclastogenesis, oxLDL inhibits the dif-
ferentiation into mature cells by interfering with the ITAM co-
stimulatory pathway.
In another study, Dawodu et al. showed that oxLDL stimulation of
human OCPs from peripheral blood impaired osteoclast activity via
inhibition of CtsK secretion [62]. In our study, we also found that Ctsk
but alsoMmp9mRNA levels were sharply decreased and may contribute
to lowering of bone erosion. This makes it highly likely that oxLDL
protects from bone erosion by inhibition of resorption of both inorganic
and organic matrix.
Conflicting results have been reported in RA patients following
cholesterol-lowering therapies. Whereas the use of statins is beneficial
in managing the cardiovascular (CV) risk in RA patients [63–65], sev-
eral studies have described the risk of developing RA during statin
treatment in subjects prone to develop RA [66,67]. In line with this,
experimental studies found that mice treated with statins showed ac-
celerated onset of disease in a collagen-type II-induced arthritis (CIA)
model [68]. Our study supports the hypothesis that lowering LDL levels
may boost both initiation and progression of bone destruction locally
within an inflamed joint.
In summary, our findings suggest that high levels of LDL in com-
bination with inflammation in the knee joint leads to oxLDL that
Fig. 4. oxLDL blocks the differentiation of mononuclear pre-osteoclasts into mature osteoclasts.
Wild-type (WT) pre-osteoclasts were stimulated with 10 μg/ml LDL or oxLDL for 24 h. a) Representative photomicrograph of pre-osteoclasts either non-stimulated
(NS) and after exposure to LDL or oxLDL for 24 h. Note that oxLDL, but not LDL, was internalized as determined by Oil Red O staining. Original magnification, 200×.
b) The messenger RNA (mRNA) levels of various osteoclast-related genes were significantly down-regulated in WT pre-osteoclasts after exposure to oxLDL, whereas
Adgre1 was significantly increased. c) Photomicrographs and quantification of TRAP positive (TRAP+) cells show a strong inhibition of osteoclastogenesis upon
oxLDL. Original magnification, 100×. d) Of note, oxLDL did not affect cell viability as determined by fluorescence intensity (FI) signals of DAPI stain. Error bars
represent the mean ± SEM of 6 mice. (*= P < 0.05, **= P < 0.01, ***= P < 0.001 versus NS control; #= P < 0.05, ##= P < 0.01 compared to LDL
stimulated samples).
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Fig. 5. oxLDL strongly restrains the formation of multinucleated osteoclasts and their resorptive activity at a later stage of differentiation. Wild-type (WT) multi-
nucleated osteoclasts were stimulated with 10 μg/ml LDL or oxLDL for 24 h. a) Representative photomicrographs and quantification of TRAP positive (TRAP+) cells
show a strong inhibition of osteoclastogenesis upon oxLDL, but not LDL stimulation. Original magnification, 100× b) Note that oxLDL did not affect cell viability as
determined by fluorescence intensity (FI) signals of DAPI stain (n= 6 mice). c) Representative photomicrographs and quantification of resorption on biomimetic
hydroxyapatite-like–coated plates show a significant reduction of pit areas upon exposure of both pre-osteoclasts (day 3) and multinucleated osteoclasts (day 5) to
oxLDL; of note, exposure to LDL reduced pit formation, though this reduction was not significant (n= 6 mice). Original magnification, 100× d) Finally, TRAP
activity in the culture supernatants of WT mature osteoclasts was strongly down-regulated both upon exposure of pre-osteoclasts (day 3) and multinucleated
osteoclasts (day 5) to oxLDL, but not LDL (n= 3 mice). Error bars represent the mean ± SEM. (*= P < 0.05, **= P < 0.01, ***= P < 0.001 compared to NS
controls; ##= P < 0.01, ###= P < 0.001 compared to LDL stimulated samples).
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inhibits bone destruction probably by suppressing osteoclast differ-
entiation via decreased activation of the ITAM co-stimulatory pathway.
Our study suggests that LDL-lowering therapies that are often used to
reduce CV risk in RA patients should be used with caution since low-
ering of local levels of LDL within the inflamed joints may diminish the
suppressing mechanism induced by oxLDL leading to increased osteo-
clastogenesis and bone destruction.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bone.2019.115140.
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